Olema Pharmaceuticals, Inc.

OLMA Healthcare Biotechnology

In the quarter to June 2026, EPS fell 19.6%, free cash flow fell 54.3% and total debt was flat, each against the same quarter a year earlier.

6.58 0.29 −4.22%
Market cap
$601.1M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Current Ratio
— 16.13 0.07 74.62 32.23 12.62 12.33 10.50 9.95
Net Debt/EBITDA
— 1.52 0.02 15.73 4.01 1.90 2.50 3.06 2.82
Debt/Assets
0.00% 0.00% 0.00% 0.00% 0.80% 0.72% 0.00% 0.00% 0.56%
Debt/Equity
— 0.00 0.00 0.00 0.01 0.01 0.00 0.00 0.01
Asset Turnover
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating CF/Net income
— 0.99 0.71 0.83 0.71 0.78 0.87 0.81 0.90
Capex/Depreciation
— 0.00 0.00 (5.09) (3.59) (1.02) 0.04 (0.40) 0.00
Interest Coverage
— (74.25) (617.57) (32.97) (161.74) (48.02) — — —
ROE
— 26.04% 51.16% (14.65%) (22.83%) (43.47%) (42.82%) (39.07%) (36.61%)
ROA
— (134.33%) (253.66%) (13.99%) (22.26%) (40.97%) (39.24%) (35.57%) (33.00%)
ROIC
— 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
— (71.63%) 345.56% (7.11%) (25.11%) (54.48%) (39.47%) (32.64%) (35.04%)
Average Days of Receivables
— — — — — 0.00 — — —
Research and Development Expense of Revenue
— 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Selling, General and Administrative Expense of Revenue
— 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Intangible Assets out of Total Assets
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Share Based Compensation of Revenue
— 0.00% — 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Free Cash Flow per Share
— (0.86) (1.19) (2.84) (1.32) (2.06) (1.85) (1.78) (1.69)
Cash per Share
— 1.25 0.03 48.22 7.27 5.11 5.79 7.39 5.81
Shareholders Equity per Share
— 1.22 (0.48) 48.16 7.20 4.94 5.61 6.96 5.50
Interest Debt per Share
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Book value per Share
— 1.22 (0.48) 48.16 7.20 4.94 5.61 6.96 5.50
Free Cash Flow
— (2.18) (3.08) (19.92) (52.26) (82.43) (83.71) (104.51) (146.72)
Working Capital
— 3.04 (1.27) 337.55 281.67 192.35 244.89 396.72 463.65
Capital Expenditures
— — — (0.06) (1.57) (0.36) 0.01 (0.16) —
Net Current Asset Value
— 3.04 (1.27) 337.55 279.31 190.80 243.46 396.46 460.58
Other line items
Quick Ratio
— 15.67 0.05 73.84 31.85 12.35 12.11 10.40 9.76
Depreciation/Fixed assets
— 0.31 0.35 0.15 0.30 0.00 0.00 0.00 0.00
Cash ROIC
— (34.99%) 261.54% (2.94%) (9.10%) (20.43%) (16.23%) (12.40%) (14.86%)
Accounts Payable Turnover
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover
— 0.00 0.00 0.00 0.00 0.00 — — —
Average Days of Payables
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days of Inventory on Hand
— 0.00 0.00 0.00 0.00 0.00 — — —
Revenue per Share
— 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating CF per Share
— (0.86) (1.19) (2.83) (1.28) (2.05) (1.85) (1.78) (1.69)
Capex per Share
— 0.00 0.00 (0.01) (0.04) (0.01) 0.00 0.00 0.00
Average Payables
— 0.53 0.53 0.83 0.37 0.20 1.54 3.58 6.86
Average Assets
— 1.64 1.70 171.43 319.33 255.80 246.30 363.96 492.20
Average Common Equity
— (8.44) (8.44) 163.77 311.35 241.06 225.72 331.43 443.76
Capex to Sales
— — — 0.00 0.00 0.00 0.00 0.00 —

Fold the line items

Columns are period end dates